ScholarIQanswers from OpenAlex
Alnylam Pharmaceuticals
FunderResearch funding and supported work
Alnylam Pharmaceuticals is a funder indexed in ScholarIQ from OpenAlex.
What is known about Alnylam Pharmaceuticals?
ScholarIQrecord summary
biopharmaceutical company
How many works does Alnylam Pharmaceuticals have?
ScholarIQindexed works
Alnylam Pharmaceuticals has 2,232 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Alnylam Pharmaceuticals?
ScholarIQopenalex
The OpenAlex for Alnylam Pharmaceuticals is on the source record.
What is the ROR of Alnylam Pharmaceuticals?
ScholarIQror
The ROR for Alnylam Pharmaceuticals is on the source record.
What are the most-cited papers on Alnylam Pharmaceuticals?
ScholarIQmost cited works
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge, Tak Mao Chan, H. Terence Cook, Fernando C. Fervenza, Keisha L. Gibson, Richard J. Glassock, David Jayne, Vivekanand Jha, Adrian Liew, Zhi-Hong Liu, Juan M. Mejía‐Vilet, Carla Nester, Jai Radhakrishnan, Elizabeth M. Rave, Heather N. Reich, Pierre Ronco, Jan‐Stephan Sanders, Sanjeev Sethi, Yusuke Suzuki, Sydney Tang, Vladimı́r Tesař, Marina Vivarelli, Jack F.M. Wetzels, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Jürgen Floege
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, Hiddo J.L. Heerspink, Inder S. Anand, Michael Böhm, Vijay Chopra, Rudolf A. de Boer, Akshay S. Desai, Junbo Ge, Masafumi Kitakaze, Bela Merkley, Eileen O’Meara, Morten Shou, С. Н. Терещенко, Subodh Verma, Pham Nguyễn Vinh, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, John J.V. McMurray
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W. Mahaffey, Meg Jardine, Séverine Bompoint, Christopher P. Cannon, Bruce Neal, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A. Pollock, Tao Sun, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M. Brenner, Vlado Perkovic, On behalf of the CREDENCE Study Investigators
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff
The pathogenesis of IgA nephropathy and implications for treatment
Chee Kay Cheung, Suceena Alexander, Heather N. Reich, Haresh Selvaskandan, Hong Zhang, Jonathan Barratt